Announcements Trials
Browse Landscape

Phase

Phase 1 9Phase 2 4Phase 3 2Phase 1/2 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 1

Conditions

Leukemia, Myeloid, Acute 4Myelodysplastic Syndromes 2Neoplasm, Residual 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Cytarabine 197Azacitidine 143Cyclophosphamide 136fludarabine phosphate 112fludarabine 97Busulfan 96venetoclax 95Mycophenolic Acid 82Whole-Body Irradiation 81Tacrolimus 78Peripheral Blood Stem Cell Transplantation 78Decitabine 62Filgrastim 56Granulocyte Colony-Stimulating Factor 54Cyclosporine 53Melphalan 52Methotrexate 51Idarubicin 51Daunorubicin 49Antilymphocyte Serum 47Clofarabine 43Etoposide 41Thiotepa 35Gemtuzumab 34Mitoxantrone 32Stem Cell Transplantation 31CPX-351 27Specimen Handling 25Radiotherapy 25thymoglobulin 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Myeloid, Acute × pevonedistat × Clear all
NCT04266795 2025-10-21

PEVENAZA

Takeda

Phase 2 Completed
164 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03745352 2023-06-27

Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 2 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02610777 2022-09-19

An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)

Takeda

Phase 2 Completed
120 enrolled 39 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03709576 2020-12-16

Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML

Milton S. Hershey Medical Center

Phase 2 Terminated
3 enrolled 9 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡